

SAFETY DATA SHEET

SECTION 1 : IDENTIFICATION

Product Name: **Fludarabine Phosphate Injection, USP**
Manufacturer Name: Fresenius Kabi USA, LLC
Address: Three Corporate Drive
 Lake Zurich, Illinois 60047
General Phone Number: (847) 550-2300
Customer Service Phone Number: (888) 386-1300
Health Issues Information: (800) 551-7176
SDS Creation Date: January 08, 2009
SDS Revision Date: February 19, 2024

SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Pictograms:



Signal Word:

WARNING.

GHS Class:

Reproductive toxicity. Category 2.
 Reproductive toxicity. Effects on or via lactation.

Hazard Statements:

Suspected of damaging fertility or the unborn child.
 May cause harm to breast-fed children.

Precautionary Statements:

Obtain special instructions before use.
 Do not handle until all safety precautions have been read and understood.
 Do not breathe dust/fume/gas/mist/vapours/spray.
 Avoid contact during pregnancy and while nursing.
 Wash hands thoroughly after handling.
 Do not eat, drink or smoke when using this product.
 Wear protective gloves/protective clothing/eye protection/face protection.
 IF exposed or concerned: Get medical advice/attention.
 Store locked up.
 Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

Emergency Overview:

This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure:

Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eye:

Contact with eyes may cause irritation.

Signs/Symptoms:

Potential adverse reactions from prescribed doses are described in the package insert. Warnings include life-threatening and sometimes fatal autoimmune hemolytic anemia. Adverse effects include: myelosuppression, fever, chills, infection, nausea, vomiting, fatigue, pain, malaise, diaphoresis, alopecia, weakness, paresthesia, headache, cough, pneumonia, dyspnea, diarrhea, anorexia, stomatitis, rash, dysuria, edema, and myalgia.

There are clear, dose-dependent toxic effects seen with fludarabine. High doses of fludarabine phosphate have been associated with irreversible central nervous system toxicity characterized by delayed blindness, coma, and death. High doses are also associated with severe thrombocytopenia and neutropenia due to bone marrow suppression. There is no known specific antidote for fludarabine phosphate overdosage. Treatment consists of drug discontinuation and supportive therapy.

Fludarabine in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia (CLL) has been associated with a high incidence of fatal pulmonary toxicity in clinical trials, therefore, the use of fludarabine in combination with pentostatin is not recommended.

Occupational exposure has not been fully investigated.

Aggravation of Pre-Existing Conditions:

Individuals with hypersensitivity to Fludarabine Phosphate Injection or any of its components.

SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Fludarabine Phosphate	75607-67-9	25 mg/mL	
Mannitol	69-65-8	25 mg/mL	
Water for Injection	7732-18-5	Quantity Sufficient	

SECTION 4 : FIRST AID MEASURES

Eye Contact:	Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.
Skin Contact:	Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.
Inhalation:	If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.
Ingestion:	If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.
Other First Aid:	For Adverse Event Information, please call (800) 551-7176.

SECTION 5 : FIRE FIGHTING MEASURES

Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.
Lower Flammable/Explosive Limit:	Not established.
Upper Flammable/Explosive Limit:	Not established.
Fire Fighting Instructions:	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
Extinguishing Media:	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Protective Equipment:	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
Hazardous Combustion Byproducts:	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

Personal Precautions:	Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.
Environmental Precautions:	Avoid runoff into storm sewers, ditches, and waterways.
Methods for containment:	Contain spills with an inert absorbent material such as soil, sand or oil dry.
Methods for cleanup:	Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

Handling:	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
Storage:	Store at refrigerated temperatures 2 to 8°C (36 to 46°F).
Work Practices:	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Hygiene Practices:	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls:	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
Eye/Face Protection:	Chemical splash goggles. Wear a face shield also when splash hazard exist.
Skin Protection Description:	Protective laboratory coat, apron, or disposable garment recommended.
Hand Protection Description:	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (<http://www.cdc.gov/niosh/npptl/topics/respirators/>) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

Physical State: Liquid solution.
Color: Colorless.
Boiling Point: Approximately 100°C
Melting Point: 0°C (32 °F)
Solubility: Soluble. in water.
Vapor Density: Not established.
Vapor Pressure: Not established.
Percent Volatile: Not established.
pH: 6.0 - 7.1
Molecular Formula: Mixture
Molecular Weight: 365.2
Flash Point: Not established.
Flash Point Method: Not established.
Auto Ignition Temperature: Not established.

SECTION 10 : STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.
Hazardous Polymerization: Not reported.
Conditions to Avoid: No conditions contributing to instability are known to exist for normal handling of this product.

SECTION 11 : TOXICOLOGICAL INFORMATION

Fludarabine Phosphate :

Acute Toxicity: LD50 IV: Male Rat 910 mg/kg
LD50 IV: Female Rat 1050 mg/kg
LD50 IV: Male Mouse 1404 mg/kg
LD50 IV: Female Mouse 1235 mg/kg
LD50 IV: Mouse - combined 1321 mg/kg
LD50 (five daily doses) IV: Male Mouse 593 mg/kg
LD50 (five daily doses) IV: Female Mouse 496 mg/kg
LD50 (five daily doses) IV: Mouse - combined 542 mg/kg

Teratogenicity: Pregnancy Category D: Fludarabine may cause fetal harm when administered to pregnant women. There are no adequate and well-controlled studies in pregnant women.

Fludarabine Phosphate :

RTECS Number: UO7440900

Other Toxicological Information: Intravenous. - Mouse LD50: 1236 mg/kg [Behavioral - somnolence (general depressed activity)]
Intravenous. - Human TDLo: 4.380 mg/kg/168D (intermittent) [Blood - lymphoma, including Hodgkin's disease Tumorigenic - protects against induction of experimental tumors Tumorigenic - active as anti-cancer agent]

Mannitol :

RTECS Number: OP2060000

Ingestion: Oral - Rat LD50: 13500 mg/kg [Details of toxic effects not reported other than lethal dose value]
Oral - Mouse LD50: 22 gm/kg [Behavioral - Somnolence (general depressed activity); Gastrointestinal - Ulceration or bleeding from small intestine]

Other Toxicological Information: Intravenous. - Rat LD50: 9690 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intravenous. - Mouse LD50: 7470 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Mouse LD50: 14 gm/kg [Details of toxic effects not reported other than lethal dose value]

SECTION 12 : ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.
Environmental Stability: No environmental information found for this product.

SECTION 13 : DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14 : TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated.
DOT UN Number: Not Regulated.

SECTION 15 : REGULATORY INFORMATION

Mannitol:

TSCA Inventory Status: Listed
EINECS Number: 200-711-8
Canada DSL: Listed

SECTION 16 : ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 2*
HMIS Fire Hazard: 0
HMIS Reactivity: 0
HMIS Personal Protection: X

SDS Creation Date: January 08, 2009

SDS Revision Date: February 19, 2024

SDS Revision Notes: Overall SDS review - no changes to formulation. Added HMIS ratings for Health, Flammability, Reactivity, and Personal Protective Equipment (PPE).

Disclaimer: The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2018 Enviance. All Rights Reserved.